Shire upgrades Baxalta cost savings after Q2 earnings beat

Drugmaker Shire upgraded its guidance for 2016 on Tuesday, after it hiked the predicted cost saving target for its $32 billion acquisition of rare disease drugs specialist Baxalta and soundly beat forecasts ...